Antimicrobial Resistance — MCQs

Antimicrobial Resistance Indian Medical PG Practice Questions and MCQs

Question 11: Which of the following cancers is NOT associated with Human Papilloma virus?

A. Cervical cancer
B. Testicular cancer (Correct Answer)
C. Vulval cancer
D. Oropharyngeal cancer

Explanation: **Explanation:** Human Papillomavirus (HPV) is a small, double-stranded DNA virus with a strong tropism for **squamous epithelial cells**. It integrates its DNA into the host genome, leading to the overexpression of oncoproteins **E6 and E7**, which inhibit tumor suppressor proteins **p53 and pRb**, respectively. This process drives malignant transformation in specific anatomical sites. **Why Testicular Cancer is the Correct Answer:** Testicular cancer (most commonly Germ Cell Tumors like Seminomas) is primarily associated with genetic factors, cryptorchidism, and Klinefelter syndrome. It is **not** caused by viral integration or HPV infection. The epithelium of the testes is not a target for HPV-mediated oncogenesis. **Why the other options are incorrect:** * **Cervical Cancer:** HPV is the primary etiological agent in >99% of cases, particularly high-risk strains **16 and 18**. * **Vulval Cancer:** A significant proportion of vulvar squamous cell carcinomas (especially the basaloid and warty types) are HPV-related. * **Oropharyngeal Cancer:** There is a rising incidence of HPV-associated squamous cell carcinoma of the oropharynx (specifically the tonsils and base of tongue), often linked to HPV-16. **High-Yield Clinical Pearls for NEET-PG:** * **High-risk HPV types:** 16, 18 (most common), 31, 33, 45. * **Low-risk HPV types:** 6, 11 (cause Genital Warts/Condyloma Acuminata). * **Other HPV-associated cancers:** Anal cancer and Penile cancer. * **Vaccination:** The Quadrivalent vaccine (Gardasil) targets types 6, 11, 16, and 18. * **Screening:** HPV DNA testing is now preferred over or used in conjunction with Pap smears for cervical cancer screening.

Question 12: Which bacterium is known for producing a potent exotoxin?

A. Clostridium tetani (Correct Answer)
B. Pseudomonas
C. Shigella
D. Klebsiella

Explanation: **Explanation:** The correct answer is **Clostridium tetani**. This bacterium is the classic example of a pathogen whose virulence is almost entirely dependent on the production of a potent exotoxin called **Tetanospasmin**. **Why Clostridium tetani is correct:** * **Tetanospasmin** is an A-B type neurotoxin and one of the most poisonous substances known (the lethal dose for humans is approximately 2.5 ng/kg). * **Mechanism:** It acts by blocking the release of inhibitory neurotransmitters (**GABA and Glycine**) from Renshaw cells in the spinal cord. This leads to unopposed muscle contraction, resulting in the characteristic clinical features of tetanus (lockjaw, opisthotonus). **Why other options are incorrect:** * **Pseudomonas aeruginosa:** While it produces Exotoxin A (which inhibits protein synthesis via EF-2), its pathogenicity is multifactorial, involving endotoxins, enzymes (elastase), and biofilm formation. It is not primarily defined by a single "potent" exotoxin in the same clinical context as C. tetani. * **Shigella:** *Shigella dysenteriae* produces Shiga toxin (Stx), which is potent and causes HUS, but other species (like *S. sonnei*) are more common and less toxigenic. The primary pathology is mucosal invasion. * **Klebsiella:** This is a Gram-negative coliform whose primary virulence factor is a thick **polysaccharide capsule**. It does not produce a classic potent exotoxin; its systemic effects are driven by **Endotoxin (LPS)**. **High-Yield Clinical Pearls for NEET-PG:** * **Retrograde Axonal Transport:** Tetanospasmin travels from the peripheral nerve endings to the CNS via retrograde transport. * **Zinc Metalloprotease:** The toxin acts as a protease that cleaves **SNARE proteins** (specifically synaptobrevin), preventing vesicle fusion. * **Formaldehyde Treatment:** Tetanus toxin is easily neutralized by formaldehyde to create the **Tetanus Toxoid** used in DPT/Tdap vaccines.

Question 13: What is the most important mechanism by which Gram-negative bacilli acquire chloramphenicol resistance?

A. Decreased permeability into the bacterial cell
B. Acquisition of a plasmid encoding chloramphenicol acetyltransferase (Correct Answer)
C. Lowered affinity of the bacterial ribosome for chloramphenicol
D. Switching over from ribosomal to mitochondrial protein synthesis

Explanation: ### **Explanation** **Correct Option: B (Acquisition of a plasmid encoding chloramphenicol acetyltransferase)** Chloramphenicol acts by binding to the **50S ribosomal subunit**, inhibiting the enzyme peptidyl transferase. The most clinically significant and common mechanism of resistance in Gram-negative bacilli (such as *Salmonella typhi* and *E. coli*) is the production of the enzyme **Chloramphenicol Acetyltransferase (CAT)**. This enzyme is typically encoded on a **plasmid (R-factor)**. CAT covalently attaches an acetyl group from acetyl-CoA to the chloramphenicol molecule, preventing it from binding to the bacterial ribosome, thereby neutralizing the drug. **Analysis of Incorrect Options:** * **Option A:** While decreased permeability (due to porin mutations) can contribute to resistance, it is rarely the primary or "most important" mechanism compared to enzymatic inactivation. * **Option C:** Alteration of the ribosomal target site is a common resistance mechanism for macrolides and clindamycin, but it is an infrequent cause of chloramphenicol resistance in clinical Gram-negative isolates. * **Option D:** Bacteria do not possess mitochondria; they are prokaryotes. This option is biologically incorrect. However, chloramphenicol *does* inhibit human mitochondrial ribosomes, which explains its toxicity (e.g., bone marrow suppression). --- ### **High-Yield NEET-PG Pearls** * **Mechanism of Action:** Bacteriostatic; inhibits protein synthesis by binding to the **50S subunit** (blocks peptidyl transferase). * **Gray Baby Syndrome:** Occurs in neonates due to a deficiency of **glucuronyl transferase**, leading to drug accumulation. * **Bone Marrow Toxicity:** Can cause dose-related suppression or idiosyncratic **Aplastic Anemia** (most serious side effect). * **Drug of Choice:** Historically used for Typhoid fever, but resistance (via CAT) has limited its use; now primarily used for bacterial meningitis in penicillin-allergic patients or in resource-limited settings.

Question 14: Which drug is used to treat Nalidixic acid resistant Salmonella typhi (NARST)?

A. Chloramphenicol
B. Azithromycin (Correct Answer)
C. Ciprofloxacin
D. Septran

Explanation: **Explanation:** The treatment landscape for Enteric Fever (Typhoid) has evolved significantly due to the emergence of multidrug-resistant (MDR) strains. **1. Why Azithromycin is the Correct Choice:** Nalidixic acid resistance in *Salmonella typhi* is a surrogate marker for "decreased ciprofloxacin susceptibility." When a strain is identified as **NARST (Nalidixic Acid Resistant Salmonella typhi)**, it indicates that fluoroquinolones like Ciprofloxacin will likely result in clinical failure or delayed response. According to current clinical guidelines (including WHO and updated Harrison’s), **Azithromycin** is the preferred oral drug for uncomplicated NARST cases due to its excellent intracellular penetration and low rates of resistance. For complicated or severe NARST, intravenous Ceftriaxone is the drug of choice. **2. Analysis of Incorrect Options:** * **Ciprofloxacin:** Previously the gold standard, it is now avoided in NARST because Nalidixic acid resistance implies mutations in the *gyrA* gene, leading to high-level fluoroquinolone resistance. * **Chloramphenicol:** This was the historical drug of choice but fell out of favor due to the emergence of MDR strains (resistance to Chloramphenicol, Ampicillin, and Septran) and risks of bone marrow toxicity. * **Septran (TMP-SMX):** Like Chloramphenicol, widespread plasmid-mediated resistance makes it unreliable for empirical therapy in the current epidemiological climate. **3. Clinical Pearls for NEET-PG:** * **DOC for Uncomplicated Typhoid:** Ceftriaxone (or Azithromycin if NARST). * **DOC for Carriers:** Ciprofloxacin (for 4–6 weeks) is used for fecal carriers (gallbladder colonization), provided the strain is susceptible. * **Screening:** Nalidixic acid disk diffusion (30 µg) is used in labs to screen for fluoroquinolone resistance. * **Most common cause of death in Typhoid:** Intestinal perforation (usually in the 3rd week).

Question 15: Methicillin resistance in Staph. aureus is due to:

A. beta-lactamase
B. MECA gene (Correct Answer)
C. AMPC gene
D. Porin development

Explanation: **Explanation:** **Correct Answer: B. MECA gene** Methicillin-resistant *Staphylococcus aureus* (MRSA) is primarily mediated by the **mecA gene**, which is carried on a mobile genetic element called the Staphylococcal Cassette Chromosome mec (SCCmec). This gene encodes an altered Penicillin-Binding Protein known as **PBP2a**. Unlike normal PBPs, PBP2a has a very low affinity for almost all beta-lactam antibiotics (penicillins, cephalosporins, and carbapenems). Consequently, even in the presence of these drugs, PBP2a continues to cross-link the bacterial peptidoglycan layer, allowing the cell wall to remain intact. **Analysis of Incorrect Options:** * **A. Beta-lactamase:** While *S. aureus* produces penicillinase (a beta-lactamase), this enzyme only confers resistance to natural penicillins (like Penicillin G). Methicillin was specifically designed to be resistant to these enzymes; therefore, MRSA resistance is due to target site modification (PBP2a), not enzymatic degradation. * **C. AMPC gene:** AmpC genes encode Class C beta-lactamases, typically found in Gram-negative bacteria (e.g., *Enterobacter*, *Serratia*). They provide resistance to cephalosporins and are not the mechanism for MRSA. * **D. Porin development:** Porin loss or mutation is a common mechanism of resistance in Gram-negative bacteria (like *Pseudomonas*) to prevent drug entry. As a Gram-positive organism, *S. aureus* lacks an outer membrane and porins. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice for MRSA:** Vancomycin (Glycopeptide). * **Exception:** Ceftaroline (5th gen cephalosporin) is the only beta-lactam that can bind to PBP2a and treat MRSA. * **Screening:** Cefoxitin disk diffusion is the preferred method to detect MRSA in labs (better inducer of the meca gene than methicillin). * **Gold Standard:** PCR to detect the *mecA* gene.

Question 16: Which gene is responsible for isoniazid resistance in Mycobacterium tuberculosis?

A. KAT G (Correct Answer)
B. rpo B
C. pnc A
D. emb B

Explanation: **Explanation:** **1. Why KAT G is Correct:** Isoniazid (INH) is a **prodrug** that must be activated within the mycobacterial cell to exert its bactericidal effect. The enzyme responsible for this activation is **Catalase-peroxidase**, which is encoded by the **katG gene**. Mutations in *katG* (most commonly the Ser315Thr mutation) lead to a loss or reduction of enzyme activity, preventing the conversion of INH into its active form (isonicotinic acyl radical). This is the most common mechanism of high-level resistance to Isoniazid. *Note: Low-level resistance can also occur via mutations in the inhA gene (target site).* **2. Why the Other Options are Incorrect:** * **B. rpo B:** This gene encodes the β-subunit of DNA-dependent RNA polymerase. Mutations here are responsible for resistance to **Rifampicin**. It is a key marker for Multidrug-Resistant TB (MDR-TB). * **C. pnc A:** This gene encodes the enzyme pyrazinamidase, which converts the prodrug **Pyrazinamide** into its active form, pyrazinoic acid. Mutations lead to Pyrazinamide resistance. * **D. emb B:** This gene is involved in the synthesis of the mycobacterial cell wall (arabinosyltransferase). Mutations in *embB* result in resistance to **Ethambutol**. **3. High-Yield Clinical Pearls for NEET-PG:** * **MDR-TB Definition:** Resistance to at least Isoniazid and Rifampicin. * **XDR-TB Definition:** MDR-TB plus resistance to any fluoroquinolone and at least one second-line injectable drug (or Bedaquiline/Linezolid under newer WHO definitions). * **Diagnostic Gold Standard:** Molecular methods like **CBNAAT (GeneXpert)** primarily detect *rpoB* mutations, while **Line Probe Assay (LPA)** can detect both *katG/inhA* and *rpoB* mutations.

Question 17: Which method is best for diagnosing Giardiasis?

A. Complement Fixation Test (CFT)
B. Cysts and trophozoites in stool (Correct Answer)
C. Hemagglutination test
D. None of the above

Explanation: **Explanation:** The diagnosis of **Giardiasis** (caused by *Giardia lamblia*) primarily relies on the direct visualization of the parasite in the patient's excreta. **1. Why Option B is correct:** Microscopic examination of **stool** remains the gold standard for diagnosis. * **Cysts:** These are the infective and more stable forms, typically found in formed or semi-formed stools. * **Trophozoites:** These are the motile, "pear-shaped" vegetative forms with a characteristic "falling leaf" motility, usually seen in diarrheal (liquid) stools. Because *Giardia* is excreted inconsistently (erratic shedding), examining three stool samples collected on different days increases the sensitivity to over 90%. **2. Why other options are incorrect:** * **Options A & C (CFT and Hemagglutination):** These are serological tests used to detect antibodies. While they exist, they are **not** used for routine diagnosis of Giardiasis because they cannot distinguish between a past and current infection. Serology is more useful in invasive protozoal infections (like Amoebic liver abscess), whereas *Giardia* is a non-invasive luminal parasite. **High-Yield Clinical Pearls for NEET-PG:** * **String Test (Entero-test):** Used if stool microscopy is repeatedly negative but clinical suspicion is high. The patient swallows a weighted gelatin capsule to sample duodenal contents. * **Antigen Detection:** Enzyme Immunoassays (ELISA) or Immunochromatographic tests for *Giardia* specific antigens (GSA 65) in stool are highly sensitive and increasingly used. * **Morphology:** Look for the "Old Man with Glasses" appearance (two nuclei and four pairs of flagella) in trophozoites. * **Treatment:** Tinidazole (Single dose) is the drug of choice; Metronidazole is an alternative.

Question 18: Eth-A gene mutation can lead to cross resistance of Ethionamide with which of the following drugs?

A. PAS
B. Isoniazid
C. Ethambutol
D. Thioacetazone (Correct Answer)

Explanation: **Explanation:** The correct answer is **Thioacetazone**. **Mechanism of Resistance:** Ethionamide is a prodrug used in the treatment of multidrug-resistant tuberculosis (MDR-TB). It requires activation by the monooxygenase enzyme encoded by the **ethA gene**. Mutations in the *ethA* gene lead to a loss of enzyme activity, preventing the conversion of the prodrug into its active form. **Thioacetazone**, another second-line antitubercular drug, is also a prodrug that requires activation by the same **ethA-encoded monooxygenase**. Therefore, a single mutation in the *ethA* gene results in cross-resistance between Ethionamide and Thioacetazone. **Analysis of Incorrect Options:** * **A. PAS (Para-aminosalicylic acid):** Resistance is primarily due to mutations in the *folP* gene or *thyA* gene, affecting the folate synthesis pathway. * **B. Isoniazid (INH):** While Ethionamide and INH share a common structural target (InhA enzyme), leading to cross-resistance via ***inhA* promoter mutations**, the *ethA* mutation specifically affects the activation step unique to Ethionamide and Thioacetazone, not INH (which is activated by *katG*). * **C. Ethambutol:** Resistance is typically due to mutations in the *embB* gene, which encodes arabinosyltransferase. **High-Yield Clinical Pearls for NEET-PG:** * **EthA mutation:** Causes cross-resistance between Ethionamide and Thioacetazone. * **InhA mutation:** Causes cross-resistance between **Isoniazid and Ethionamide** (due to a shared target). * **KatG mutation:** Most common cause of high-level Isoniazid resistance; does **not** cause cross-resistance with Ethionamide. * **Thioacetazone Caution:** It is notorious for causing severe cutaneous adverse drug reactions (e.g., Stevens-Johnson Syndrome), especially in HIV-positive patients.

Question 19: Which of the following antimicrobial agents is effective against an organism producing extended-spectrum beta-lactamase (ESBL)?

A. Amoxicillin-Clavulanic acid
B. Cefepime
C. Piperacillin-Tazobactam (Correct Answer)
D. Ceftriaxone

Explanation: ### Explanation **Core Concept: Extended-Spectrum Beta-Lactamases (ESBLs)** ESBLs are enzymes produced primarily by Gram-negative bacteria (like *E. coli* and *Klebsiella*) that mediate resistance to most beta-lactam antibiotics, including third and fourth-generation cephalosporins and monobactams (aztreonam). However, they are typically inhibited by **beta-lactamase inhibitors** (clavulanic acid, sulbactam, tazobactam) and remain susceptible to **Carbapenems**. **Why Piperacillin-Tazobactam is Correct:** Piperacillin-Tazobactam is a combination of a ureidopenicillin and a potent beta-lactamase inhibitor. Tazobactam effectively neutralizes the ESBL enzyme, allowing Piperacillin to exert its bactericidal effect. In clinical practice, while Carbapenems are the "gold standard" for serious ESBL infections, Piperacillin-Tazobactam is a recognized "carbapenem-sparing" option for non-bacteremic urinary tract infections caused by ESBL-producing organisms. **Analysis of Incorrect Options:** * **Amoxicillin-Clavulanic acid (A):** While clavulanic acid inhibits ESBLs, Amoxicillin has a narrow spectrum and poor intrinsic activity against the heavy Gram-negative loads typically associated with ESBL-producing *Enterobacteriaceae*. * **Cefepime (B) & Ceftriaxone (D):** ESBLs specifically hydrolyze oxyimino-cephalosporins. Ceftriaxone (3rd gen) and Cefepime (4th gen) are rendered ineffective by these enzymes. A "positive ESBL test" is traditionally defined by the inability of these drugs to work unless paired with an inhibitor. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Carbapenems (e.g., Meropenem, Imipenem) are the treatment of choice for serious/systemic ESBL infections. * **Detection:** ESBL production is suspected when there is resistance to **Cefotaxime, Ceftazidime, or Ceftriaxone**. * **Confirmatory Test:** Phenotypic disc diffusion test showing a $\geq$ 5mm increase in zone diameter for Ceftazidime when tested in combination with Clavulanic acid versus Ceftazidime alone. * **Gene Association:** Most common ESBL genotypes are **CTX-M** (now the most prevalent worldwide), TEM, and SHV.

Question 20: Which of the following statements is false regarding extended-spectrum beta-lactamases (ESBL)?

A. These can hydrolyze penicillins, cephalosporins, and monobactams.
B. Carbapenems are susceptible to ESBL. (Correct Answer)
C. Amber classification of ESBL is based on structural differences.
D. Third and fourth-generation cephalosporins are used for the detection of ESBL.

Explanation: ### Explanation **Extended-Spectrum Beta-Lactamases (ESBLs)** are enzymes produced primarily by Gram-negative bacteria (like *E. coli* and *Klebsiella*) that confer resistance to a wide range of beta-lactam antibiotics. **Why Option B is the Correct Answer (False Statement):** Carbapenems (e.g., Meropenem, Imipenem) are **not** susceptible to hydrolysis by ESBLs. In fact, carbapenems are the **drugs of choice** for treating serious infections caused by ESBL-producing organisms. If an organism becomes resistant to carbapenems, it is usually due to a different enzyme called a carbapenemase (e.g., NDM-1). **Analysis of Other Options:** * **Option A (True):** ESBLs are defined by their ability to hydrolyze penicillins, first- to fourth-generation cephalosporins, and monobactams (Aztreonam). * **Option C (True):** The **Ambler Classification** categorizes beta-lactamases based on their molecular/structural amino acid sequences. ESBLs typically belong to **Class A** (e.g., TEM, SHV, CTX-M) or **Class D**. * **Option D (True):** Phenotypic detection of ESBL in the lab involves testing the organism's susceptibility to 3rd-generation (Ceftaxime/Ceftriaxone) and 4th-generation (Cefepime) cephalosporins, often in combination with a beta-lactamase inhibitor like Clavulanic acid. **High-Yield Clinical Pearls for NEET-PG:** 1. **Inhibitor Sensitivity:** ESBLs are typically inhibited by beta-lactamase inhibitors like **Clavulanic acid, Sulbactam, and Tazobactam**. This "reversal" of resistance is used for diagnostic confirmation (Double Disk Synergy Test). 2. **Most Common Gene:** Globally, the **CTX-M** gene is now the most prevalent type of ESBL. 3. **Treatment:** While Carbapenems are the gold standard, newer combinations like Ceftazidime-Avibactam are also effective. 4. **Co-resistance:** ESBL-producing plasmids often carry resistance genes for other classes, such as Aminoglycosides and Fluoroquinolones.

Practice by Chapter

Mechanisms of Antimicrobial Resistance

Practice Questions

Beta-lactamase Producing Organisms

Practice Questions

Methicillin-Resistant Staphylococcus aureus

Practice Questions

Vancomycin-Resistant Enterococci

Practice Questions

Carbapenem-Resistant Enterobacteriaceae

Practice Questions

Multi-drug Resistant Tuberculosis

Practice Questions

Antimicrobial Stewardship

Practice Questions

Detection of Antimicrobial Resistance

Practice Questions

Global Surveillance of Resistance

Practice Questions

New Antimicrobial Development

Practice Questions

Alternative Approaches to Antimicrobial Therapy

Practice Questions

One Health Approach to Resistance

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free